title: Donor cell-derived myelodysplastic syndrome with ring chromosome 7 after allogeneic hematopoietic stem cell transplant in 2 patients with lymphomas as primary disease.
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Amir
authors.initials: A
authors.lastname: Hamdi
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Aimaz
authors.initials: A
authors.lastname: Afrough
authors.affiliation: Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Tariq
authors.initials: T
authors.lastname: Muzzafar
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Uday R
authors.initials: UR
authors.lastname: Popat
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Chitra M
authors.initials: CM
authors.lastname: Hosing
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Muzaffar H
authors.initials: MH
authors.lastname: Qazilbash
authors.affiliation: Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: gglu@mdanderson.org.
authors.forename: Gary
authors.initials: G
authors.lastname: Lu
mesh_terms: D064591:Allografts; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D014408:Biomarkers, Tumor; D001853:Bone Marrow / Q000473:pathology; D002471:Cell Transformation, Neoplastic / Q000235:genetics*; D002872:Chromosome Deletion; D002897:Chromosomes, Human, Pair 7 / Q000235:genetics / Q000648:ultrastructure*; D003520:Cyclophosphamide / Q000008:administration & dosage; D018450:Disease Progression; D005260:Female; D017353:Gene Deletion; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D015470:Leukemia, Myeloid, Acute / Q000209:etiology* / Q000235:genetics / Q000473:pathology; D019520:Living Donors; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000628:therapy*; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000209:etiology* / Q000235:genetics / Q000473:pathology; D016609:Neoplasms, Second Primary / Q000209:etiology* / Q000473:pathology; D036102:Peripheral Blood Stem Cell Transplantation; D050783:Proto-Oncogene Proteins c-ets / Q000172:deficiency / Q000235:genetics; D012097:Repressor Proteins / Q000172:deficiency / Q000235:genetics; D012303:Ring Chromosomes; D000069283:Rituximab; D018183:Transplantation Chimera / Q000235:genetics; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000097764:ETS Translocation Variant 6 Protein
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D014408:Biomarkers, Tumor; D003520:Cyclophosphamide; D050783:Proto-Oncogene Proteins c-ets; D012097:Repressor Proteins; D000069283:Rituximab; D014740:Vidarabine; D000097764:ETS Translocation Variant 6 Protein; C422802:ibritumomab tiuxetan; C024352:fludarabine
keywords: Donor cells; MDS; Ring chromosome 7